Kodiak Sciences Stock-Based Compensation Growth & History (KOD)
Kodiak Sciences's stock-based compensation was $58.9M for fiscal 2025.
View full Kodiak Sciences company overviewKodiak Sciences annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $58.9M | −$1.4M | −2.24% |
| 2024 | 2024-12-31 | $60.2M | −$28.3M | −32.01% |
| 2023 | 2023-12-31 | $88.6M | −$17.5M | −16.48% |
| 2022 | 2022-12-31 | $106.0M | $44.6M | +72.73% |
| 2021 | 2021-12-31 | $61.4M | $30.7M | +100.16% |
| 2020 | 2020-12-31 | $30.7M | $24.6M | +401.93% |
| 2019 | 2019-12-31 | $6.1M | $3.4M | +129.27% |
| 2018 | 2018-12-31 | $2.7M | $2.4M | +869.09% |
| 2017 | 2017-12-31 | $275,000 | $3,000 | +1.10% |
| 2016 | 2016-12-31 | $272,000 | — | — |
Kodiak Sciences quarterly stock-based compensation
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $11.6M | −$4.0M | −25.78% |
| Q1 2026 | 2026-03-31 | $12.2M | −$3.7M | −23.51% |
| Q4 2025 | 2025-12-31 | $13.3M | $4.7M | +54.14% |
| Q3 2025 | 2025-09-30 | $14.0M | −$764,000 | −5.16% |
| Q2 2025 | 2025-06-30 | $15.6M | −$2.7M | −14.88% |
| Q1 2025 | 2025-03-31 | $15.9M | −$2.5M | −13.68% |
| Q4 2024 | 2024-12-31 | $8.6M | −$14.2M | −62.25% |
| Q3 2024 | 2024-09-30 | $14.8M | $864,000 | +6.20% |
| Q2 2024 | 2024-06-30 | $18.4M | −$7.4M | −28.78% |
| Q1 2024 | 2024-03-31 | $18.4M | −$7.6M | −29.14% |
| Q4 2023 | 2023-12-31 | $22.8M | −$2.9M | −11.44% |
| Q3 2023 | 2023-09-30 | $13.9M | −$12.2M | −46.73% |
| Q2 2023 | 2023-06-30 | $25.8M | −$177,000 | −0.68% |
| Q1 2023 | 2023-03-31 | $26.0M | −$2.1M | −7.53% |
| Q4 2022 | 2022-12-31 | $25.8M | −$2.2M | −7.92% |
| Q3 2022 | 2022-09-30 | $26.2M | $13.8M | +111.54% |
| Q2 2022 | 2022-06-30 | $26.0M | $14.9M | +134.31% |
| Q1 2022 | 2022-03-31 | $28.1M | $18.2M | +183.07% |
| Q4 2021 | 2021-12-31 | $28.0M | $18.5M | +196.10% |
| Q3 2021 | 2021-09-30 | $12.4M | $4.1M | +50.19% |
| Q2 2021 | 2021-06-30 | $11.1M | $4.2M | +60.91% |
| Q1 2021 | 2021-03-31 | $9.9M | $3.8M | +63.19% |
| Q4 2020 | 2020-12-31 | $9.5M | $7.5M | +388.38% |
| Q3 2020 | 2020-09-30 | $8.2M | $6.5M | +364.81% |
| Q2 2020 | 2020-06-30 | $6.9M | $5.6M | +453.86% |
| Q1 2020 | 2020-03-31 | $6.1M | $4.9M | +425.67% |
| Q4 2019 | 2019-12-31 | $1.9M | $820,000 | +73.48% |
| Q3 2019 | 2019-09-30 | $1.8M | $973,000 | +121.63% |
| Q2 2019 | 2019-06-30 | $1.2M | $587,000 | +89.35% |
| Q1 2019 | 2019-03-31 | $1.2M | $1.1M | +1157.61% |
| Q4 2018 | 2018-12-31 | $1.1M | — | — |
| Q3 2018 | 2018-09-30 | $800,000 | −$68.2M | −98.84% |
| Q2 2018 | 2018-06-30 | $657,000 | — | — |
| Q1 2018 | 2018-03-31 | $92,000 | — | — |
| Q3 2017 | 2017-09-30 | $69.0M | — | — |
Kodiak Sciences stock-based compensation trends
Over the last five fiscal years, Kodiak Sciences's stock-based compensation increased from $30.7M to $58.9M, a change of $28.2M. The latest reported quarter, Q2 2026, shows $11.6M.
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kodiak Sciences source filings ↗